Biosimilars stocks
바이오시밀러
What are Biosimilars stocks in Korea?
The Biosimilars theme on jonbur groups 11 Korean stocks listed on KOSPI and KOSDAQ, worth ₩138T in total. On Oct 28, 2026 the group moved up 0.49% (weighted by market value); the largest members are Samsung Biologics, Celltrion, Alteogen.
Key facts
- Stocks
- 11
- Total market value
- ₩138T
- Day's move
- +0.49%
- As of
- Oct 28, 2026
- Largest members
- Samsung Biologics, Celltrion, Alteogen
Earnings tracker · 3Q 2026
Reporting season · reports due by Nov 14
Combined, for the companies that have reported, vs the same quarter a year ago
| Company | Reported | Revenue | vs a year ago | Operating profit | vs a year ago | vs last quarter | Op. margin |
|---|---|---|---|---|---|---|---|
| Celltrion | Oct 12Preliminary | ₩1.5T | +45.8% | ₩510B | +69.2% | +12.9% | 34.0%29.3% |
| Samsung Epis Holdings | Oct 28Preliminary | ₩442B | +0.3% | ₩133B | +2.8% | +125.8% | 30.0%29.3% |
| Samsung Biologics | Expected around Oct 28 | ||||||
| CKD Bio | Expected around Oct 31 | ||||||
| Alteogen | Expected around Nov 14 | ||||||
| SAM Chun Dang Pharm | Expected around Nov 14 | ||||||
| Celltrion Pharm | Expected around Nov 14 | ||||||
| Prestige Biologics | Expected around Nov 14 | ||||||
| Prestige BioPharma | Expected around Nov 28 | ||||||
| Inventage Lab | Expected around Dec 1 | ||||||
| IMBiologics | Not yet | ||||||
Single-quarter figures. Preliminary figures are the company's own early numbers and are replaced by the quarterly report when it's filed. Expected dates are around when each company reported a year ago.
Technical breadth
After the close on Oct 28, 2026- Above 20-day average
- 18.2%
- Above 60-day average
- 18.2%
- RSI above 70
- 0%
- RSI below 30
- 18.2%
- 52-week highs
- 0
- 52-week lows
- 2
Index gauge · Short term
Bearish
0 bullish, 2 neutral, 7 bearish
Index gauge · Medium term
Bearish
0 bullish, 1 neutral, 7 bearish
Technical read
The Biosimilars group comprises 11 Korean stocks, and only 18.2% of them trade above their 20-day and 60-day averages, indicating weak short- and medium-term breadth. Two members have touched 52-week lows while none have reached 52-week highs, and the lowest member RSI reading is 18.2 with no members showing elevated RSI. The equal-weighted member index sits below its cloud, with an RSI of 37.8, and both short-term and medium-term gauges read bearish, with seven bearish signals and no bullish ones on each horizon.
Written by AI from the indicator values above. Not advice.
Share of members, from each member's own indicators; the gauge reads an equal-weighted index of the members. Technical indicators describe past price and volume patterns. They are not predictions or recommendations.
Credit & macro
No notable credit, ELS or macro events for these companies in the last 30 days.
ETFs for this theme
All ETFs →AUM · Flow 1w
Biosimilars
−0.52%바이오시밀러
Biosimilars are copies of biologic drugs, which are complex medicines made from living cells, that are shown to be highly similar to an already-approved reference product in quality, safety, and efficacy. Korean investors group the theme together because several domestic companies, including Samsung Biologics, Celltrion, and Hanmi-linked developers, have built large manufacturing or development capabilities in this area. Because the sector sits at the intersection of pharmaceuticals, contract manufacturing, and patent-expiry timelines, the theme is often discussed as a single category even though individual companies differ in business models.
11 companies · 8 up · 0 flat · 3 down
- Traded value
- ₩239B
- Value vs 20-day average
- 0.72×
- Top gainer
- Inventage Lab +5.04%
- Largest company
- Samsung Biologics ₩64T
Companies in this theme
| Company | Price | Daily | Traded value | Market cap | NPS |
|---|---|---|---|---|---|
Samsung Biologics207940 · KOSPI | ₩1,372,000 | −0.15% | ₩69B | ₩64T | 6.88% |
Celltrion068270 · KOSPI | ₩189,800 | +0.64% | ₩80B | ₩44T | 7.28% |
Samsung Epis Holdings0126Z0 · KOSPI | ₩316,500 | +1.44% | ₩9.3B | ₩7.9T | 5.70% |
Source: KRX statistical information